Overview

* Protara Therapeutics' ( TARA ) Q2 net loss widens to $15.0 mln from $9.5 mln, missing analysts' expectations

* Adjusted EPS of -$0.35 beat analysts' estimates, per LSEG data

* Cash reserves expected to fund operations into mid-2027

Outlook

* Protara to present ADVANCED-2 trial interim results in 1Q 2026

* Company on track to dose first patient in THRIVE-3 trial in 3Q 2025

* Interim update from STARBORN-1 trial expected in 4Q 2025

* Cash reserves to support operations into mid-2027

Result Drivers

* CLINICAL TRIAL PROGRESS - Increased R&D expenses driven by ongoing trials for TARA-002 and IV Choline Chloride

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS Beat -$0.35 -$0.41

(6

Analysts

)

Q2 Net Miss -$14.96 -$13 mln

Income mln (5

Analysts

)

Q2 Miss -$16.59 -$14.10

Income mln mln (5

from Analysts

Operatio )

ns

Q2 $16.59

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Protara Therapeutics Inc ( TARA ) is $22.50, about 86.1% above its August 8 closing price of $3.13

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)